CNMD analyst estimates
CONMED (CNMD) analyst ratings, the average price target and its range, and every firm's latest call.
CNMD analyst ratings and price targets
| Date | Firm | Call | Target |
|---|---|---|---|
| Jul 13, 2026 | Wells Fargo | Wells finds Conmed sale report 'little surprising' after refinance | $39.00 |
| Jul 8, 2026 | BMO Capital | Conmed initiated with a Market Perform at BMO Capital | $36.00 |
| May 1, 2025 | Needham | Conmed price target lowered to $61 from $91 at Needham | $61.00 |
| Oct 4, 2024 | Needham | Needham Reiterates Buy Rating on CONMED (CNMD) | $97.00 |
| Apr 25, 2024 | Needham | CONMED (CNMD) PT Lowered to $107 at Needham | $107.00 |
| Apr 25, 2024 | Piper Sandler | CONMED (CNMD) PT Lowered to $95 at Piper Sandler | $95.00 |
| Oct 26, 2022 | Piper Sandler | Conmed price target lowered to $108 from $118 at Piper Sandler | $108.00 |
- 6 firms rate CNMD: 0 buy, 5 hold, 1 sell.
- The average price target is $37.50 from 2 analysts, from $36.00 to $39.00.
Updated 2026-11-02 17:54 UTC